Maintenance immunotherapy and chemo after surgery for metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies tislelizumab plus capecitabine given after surgery to help prevent metastatic colorectal cancer from coming back. It may be an option if you recently had surgery that removed visible disease and you have good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 20 and 79 years old
- Have confirmed colorectal cancer by biopsy or test results
- Have had surgery for metastatic colorectal cancer and were considered “no evidence of disease” afterward
- Have had complete tumor removal (no visible remaining tumor), especially if cancer had spread to the belly lining
- Have not had any chemotherapy before
- Be able to do normal daily activities (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This Phase 2 trial studies whether adding tislelizumab to standard chemo (CAPOX) around the time of surgery can lower the risk of colon or rectal cancer coming back. It’s for people with stage II or III tumors that have an MSI-H or dMMR test result, which may mean they’re more likely to respond to immune-based treatment.
This trial tests a chemotherapy followed by an immunotherapy drug (tislelizumab) for people with stomach or colon cancer that has certain genetic markers. It aims to prevent the cancer from coming back after surgery.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
Hear when a new Metastatic Colorectal Cancer，NED trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.